Summary
Omeros Corp (Omeros) discovers, develops and commercializes small-molecule and protein therapeutics for large-market and orphan indications targeting inflammation, coagulopathies and central nervous system disorders. The company’s pipeline products include Omidria, a phenylephrine and ketorolac injection and its product candidates are intended for the treatment of ophthalmological, arthroscopic, urological and other surgical procedures including thrombotic microangiopathies; Huntington’s disease and cognitive impairment; complement-mediated glomerulopathies; addictive and compulsive disorders; and various urologic surgical procedures. Its preclinical product candidates are intended for treatment of bleeding disorders, alternative pathway disorders, central nervous system disorders, metabolic, oncologic, musculoskeletal and other disorders. Omeros is headquartered in Seattle, Washington, the US.
Omeros Corp (OMER) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
                     
                                   '
                        
Table of Contents
Table of Contents  2
List of Tables  3
List of Figures  4
Omeros Corp, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016  5
Omeros Corp, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016  6
Omeros Corp, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016  7
Omeros Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016  8
Omeros Corp, Medical Devices Deals, 2010 to YTD 2016  10
Omeros Corp, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016  11
Omeros Corp, Pharmaceuticals & Healthcare, Deal Details  12
Asset Purchase  12
Omeros Acquires Antibody Related Assets from Xori  12
Omeros Completes The Acquisition Of GPCR Assay Technology Assets From Patobios  13
Licensing Agreements  15
Omeros Enters into Licensing Agreement with Fagron  15
Omeros Expands Licensing Agreement With Daiichi Sankyo  16
Omeros Enters Into Licensing Agreement With Helion Biotech  17
Omeros Corporation Enters Into Licensing Agreement With Asubio Pharma  18
Equity Offering  19
Omeros Prices Public Offering of Shares for USD40 Million  19
Omeros to Raise up to USD100 Million in Public Offering of Shares  21
Omeros Raises USD84 Million in Public Offering of Shares and Pre-Funded Warrants  23
Omeros Completes Public Offering Of Shares For US$40.3 Million  25
Omeros Completes Private Placement Of Common Stock For US$16 Million  27
Omeros Announces Public Offering Of Common Stock For US$60 Million  29
Omeros Completes Public Offering Of Common Stock For US$34.5 Million  31
Omeros Announces Private Placement For US$40 Million  33
Omeros Completes Private Placement Of US$20 Million  35
Omeros Announces Private Placement Of US$40 Million With Azimuth Opportunity  37
Omeros Corp - Key Competitors  39
Key Employees  40
Locations And Subsidiaries  41
Head Office  41
Other Locations & Subsidiaries  41
Appendix  42
Methodology  42
About GlobalData  42
Contact Us  42
Disclaimer  42
List of Tables
Omeros Corp, Pharmaceuticals & Healthcare, Key Facts, 2015  1
Omeros Corp, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016  5
Omeros Corp, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016  6
Omeros Corp, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016  7
Omeros Corp, Deals By Therapy Area, 2010 to YTD 2016  8
Omeros Corp, Medical Devices Deals, 2010 to YTD 2016  10
Omeros Corp, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016  11
Omeros Acquires Antibody Related Assets from Xori  12
Omeros Completes The Acquisition Of GPCR Assay Technology Assets From Patobios  13
Omeros Enters into Licensing Agreement with Fagron  15
Omeros Expands Licensing Agreement With Daiichi Sankyo  16
Omeros Enters Into Licensing Agreement With Helion Biotech  17
Omeros Corporation Enters Into Licensing Agreement With Asubio Pharma  18
Omeros Prices Public Offering of Shares for USD40 Million  19
Omeros to Raise up to USD100 Million in Public Offering of Shares  21
Omeros Raises USD84 Million in Public Offering of Shares and Pre-Funded Warrants  23
Omeros Completes Public Offering Of Shares For US$40.3 Million  25
Omeros Completes Private Placement Of Common Stock For US$16 Million  27
Omeros Announces Public Offering Of Common Stock For US$60 Million  29
Omeros Completes Public Offering Of Common Stock For US$34.5 Million  31
Omeros Announces Private Placement For US$40 Million  33
Omeros Completes Private Placement Of US$20 Million  35
Omeros Announces Private Placement Of US$40 Million With Azimuth Opportunity  37
Omeros Corp, Key Competitors  39
Omeros Corp, Key Employees  40
Omeros Corp, Subsidiaries  41
List of Figures
Omeros Corp, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016  1
Omeros Corp, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016  1
Omeros Corp, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016  1
Omeros Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016  1
Omeros Corp, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016  5
Omeros Corp, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016  6
Omeros Corp, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016  7
Omeros Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016  8
Omeros Corp, Medical Devices Deals, 2010 to YTD 2016  10